BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27832473)

  • 1. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.
    Liu X; Ma M; Duan X; Zhang H; Yang M
    Clin Transl Oncol; 2017 May; 19(5):587-592. PubMed ID: 27832473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
    Li B; Yao Z; Wan Y; Lin D
    Oncotarget; 2016 Nov; 7(47):77342-77347. PubMed ID: 27816965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.
    Wei L; Wang XW; Sun JJ; Lv LY; Xie L; Song XR
    Asian Pac J Cancer Prev; 2015; 16(3):875-80. PubMed ID: 25735376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of basic fibroblast growth factor increases cisplatin sensitivity in A549 non-small cell lung cancer cells.
    He L; Meng Y; Zhang Z; Liu Y; Wang X
    J Cancer Res Ther; 2018; 14(7):1519-1524. PubMed ID: 30589033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
    Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
    Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
    Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
    Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
    Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
    Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
    Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
    Almeida GM; Duarte TL; Farmer PB; Steward WP; Jones GD
    Int J Cancer; 2008 Apr; 122(8):1810-9. PubMed ID: 18074354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11.
    Zagryazhskaya A; Surova O; Akbar NS; Allavena G; Gyuraszova K; Zborovskaya IB; Tchevkina EM; Zhivotovsky B
    Oncotarget; 2015 May; 6(14):12156-73. PubMed ID: 25940438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells.
    Wohlkoenig C; Leithner K; Deutsch A; Hrzenjak A; Olschewski A; Olschewski H
    Cancer Lett; 2011 Sep; 308(2):134-43. PubMed ID: 21669489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.